Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Geron Corporation's Stock Is Getting Hammered Today

By George Budwell - Sep 27, 2018 at 7:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron doesn't get the answer it was hoping for from Johnson & Johnson.

What happened

Geron's ( GERN 0.00% ) shares fell by more than 65% in pre-market trading this morning on heavy volume. The biotech's shares are cratering in response to a negative continuation decision by Johnson & Johnson ( JNJ -0.63% ) regarding the duo's blood cancer collaboration for the telomerase inhibitor imetelstat.

According to the press release, J&J has decided to return the rights to Geron due to "strategic portfolio evaluation and prioritization of assets within their portfolio." The drug's rights will effectively transition over to Geron on Sept. 28, 2018. 

Man with a laptop over his head holding a sign that reads HELP!

Image source: Getty Images.

So what

Geron's stock was up by more than 200% from its 52-week lows at one point last week, thanks to the belief that J&J would take imetelstat into late-stage testing and perhaps buy its collaborator outright. Obviously, this termination decision dashes that thesis, forcing Geron to pick up the pieces and rebuild its infrastructure to develop imetelstat alone. 

Now what

On the plus side, Geron said it does plan on advancing imetelstat into a late-stage trial to evaluate the drug in patients with low or intermediate-1 risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent. That process is expected to get underway by mid-2019.

Unfortunately, Geron reportedly decided to not raise additional capital while it had the chance to do so when its share price was north of $6. The direct consequence of this action is that Geron is eventually going to have to raise more funds at depressed share price levels to sally forth with imetelstat's development. That being said, there may be one or more other names out there willing to pick up the baton. Imetelstat, after all, is now ready for phase 3. Stay tuned.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
GERN
$1.38 (0.00%) $0.00
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$157.09 (-0.63%) $0.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.